P516: Adrenal suppression in inflammatory bowel disease patients treated with glucocorticoids: a systematic reviewECCO '17 Barcelona
2017
P519: Anti-tumour necrosis-alpha therapy during pregnancy in patients with inflammatory bowel disease: safety in women and childrenECCO '17 Barcelona
2017
P520: Perspective and self-efficacy of adolescents with inflammatory bowel disease post transition to adult careECCO '17 Barcelona
2017
P521: A prospective cohort study to assess the relevance of Vedolizumab drug level monitoring in IBD patientsECCO '17 Barcelona
2017
P522: A multicenter study to validate Magnetic Resonance Enterography against histological assessments of stenotic disease in patients with Crohn's diseaseECCO '17 Barcelona
2017
P523: Association between pharmacokinetics of adalimumab and disease outcome in Japanese patients with biologics naïve Crohn's disease: a subanalysis of DIAMOND trialECCO '17 Barcelona
2017
P524: Long-term outcomes after restorative proctocolectomy and ileal pouch-anal anastomosis in children compared to adultsECCO '17 Barcelona
2017
P525: Effectiveness and safety of vedolizumab in IBD patients: a multicentre experience of “real world data” from the UKECCO '17 Barcelona
2017
P526: A prospective 52-week mucosal healing and deep remission assessment of small bowel and colonic Crohn's disease as detected by colon capsule endoscopyECCO '17 Barcelona
2017
P527: Infliximab biosimilar switching program overseen by specialist pharmacist saves money, realises investment and optimises therapyECCO '17 Barcelona
2017
P528: Long-term outcome of ulcerative colitis patients responders to cyclosporine in the biological eraECCO '17 Barcelona
2017
P529: Impact of stress in inflammatory bowel disease. Effect of a group psychological intervention programECCO '17 Barcelona
2017
P530: Azathioprine in the maintenance of steroid-free remission in inflammatory bowel disease patients: efficacy and safety in five years of follow-upECCO '17 Barcelona
2017
P531: Discontinuation of corticosteroids among Crohn's disease patients treated with vedolizumab in the United StatesECCO '17 Barcelona
2017
P532: Biosimilar infliximab in anti-TNF naive inflammatory bowel disease patients – one-year clinical follow-upECCO '17 Barcelona
2017